Technical Analysis for ZGNX - Zogenix, Inc.

Zogenix, Inc., a pharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders and pain. Its commercial product includes Sumavel DosePro (sumatriptan injection), a delivery system that offers needle-free subcutaneous administration of sumatriptan for the acute treatment of migraine and cluster headache. The company's lead product candidate, Zohydro, a single-entity extended-release hydrocodone, which has completed Phase III clinical trials for the treatment of moderate to severe chronic pain requiring around-the-clock opioid therapy. It is also developing Relday, an injectable formulation of risperidone, which is in a Phase I clinical trial to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older. Zogenix, Inc. markets and sells its Sumavel DosePro to wholesale pharmaceutical distributors and retail pharmacies in the United States. It has a licensing and distribution agreement with Desitin Arzneimittel GmbH to develop and commercialize DosePro in the European Union, Norway, Switzerland, and Turkey. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in San Diego, California.
Chemistry Pharmaceutical Pain Schizophrenia Central Nervous System Disorders Morphinans Neurochemistry Cell Signaling European Union Ketones Migraine Bipolar Disorder Hydrocodone Severe Chronic Pain Treatment Of Central Nervous System Disorders Treatment Of Migraine Indoles Retail Pharmacies Triptans